Dr. Giri Discusses Testing for Inherited Prostate Cancer

Veda Giri, MD
Published: Thursday, Mar 22, 2018



Veda Giri, MD, associate professor, Thomas Jefferson University Hospital, discusses testing for inherited prostate cancer.

There are few scenarios in which men should consider getting tested for inherited prostate cancer, says Giri. For a man who has had metastatic disease and is progressing after going through the standard lines of therapy, genetics can inform additional options for treatment or clinical trials. There are increasing FDA indications for PARP inhibitors and checkpoint inhibitors for patients with mismatch repair-deficient cancers, says Giri.

Another group of men who may want to consider genetic testing are those who have a family history of cancer. This is not limited to prostate cancer, says Giri, but men who have a family history of breast, ovarian, pancreatic or colon cancer, as these malignancies can be linked to inherited risk for prostate cancer.


Veda Giri, MD, associate professor, Thomas Jefferson University Hospital, discusses testing for inherited prostate cancer.

There are few scenarios in which men should consider getting tested for inherited prostate cancer, says Giri. For a man who has had metastatic disease and is progressing after going through the standard lines of therapy, genetics can inform additional options for treatment or clinical trials. There are increasing FDA indications for PARP inhibitors and checkpoint inhibitors for patients with mismatch repair-deficient cancers, says Giri.

Another group of men who may want to consider genetic testing are those who have a family history of cancer. This is not limited to prostate cancer, says Giri, but men who have a family history of breast, ovarian, pancreatic or colon cancer, as these malignancies can be linked to inherited risk for prostate cancer.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x